tetano
Editor, Senior Moderator
Expert Opin Pharmacother
. 2024 Jul 12.
doi: 10.1080/14656566.2024.2376660. Online ahead of print. Considerations when treating influenza infections with oseltamivir
Chunping Gu[SUP] 1 [/SUP], Yi Chen[SUP] 2 [/SUP], Haobin Li[SUP] 3 [/SUP], Jinshen Wang[SUP] 3 [/SUP], Shuwen Liu[SUP] 3 4 5 [/SUP]
Affiliations
Introduction: Since the coronavirus disease 2019-mandated social distancing policy has been lifted worldwide, the circulation of influenza is expected to resume. Currently, oseltamivir is approved as the first-line agent for influenza prevention and treatment.
Areas covered: This paper reviews the updated evidence in the pharmacology, resistance mechanisms, clinical pharmacy management, and real-world data on oseltamivir for influenza.
Expert opinion: Oseltamivir is an oral prodrug of oseltamivir carboxylate, an influenza A and B neuraminidase inhibitor. Recently, the therapeutic efficacy of oseltamivir has been demonstrated in several trials. Oseltamivir is generally well-tolerated but may lead to neuropsychiatric events and bleeding. Oseltamivir-resistant influenza virus has been associated with the H275Y mutation in the influenza A(H1N1)pdm09 virus, while most strains are still sensitive to oseltamivir. Dose adjustment for oseltamivir should be based on creatinine clearance and body weight in pediatric patients with renal failure. According to real-world data from Nanfang Hospital, the annual number of patients prescribed oseltamivir declined from 35,711 in 2019 to 8,971 in 2020, with marked increases in 2022 (20,213) and 2023 (18,071). Among the 206 inpatients, children aged <6 years who were treated with oseltamivir had the shortest duration to defervescence.
Keywords: Clinical pharmacy management; Oseltamivir; influenza; prevention; tolerability; treatment.
. 2024 Jul 12.
doi: 10.1080/14656566.2024.2376660. Online ahead of print. Considerations when treating influenza infections with oseltamivir
Chunping Gu[SUP] 1 [/SUP], Yi Chen[SUP] 2 [/SUP], Haobin Li[SUP] 3 [/SUP], Jinshen Wang[SUP] 3 [/SUP], Shuwen Liu[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 38995220
- DOI: 10.1080/14656566.2024.2376660
Introduction: Since the coronavirus disease 2019-mandated social distancing policy has been lifted worldwide, the circulation of influenza is expected to resume. Currently, oseltamivir is approved as the first-line agent for influenza prevention and treatment.
Areas covered: This paper reviews the updated evidence in the pharmacology, resistance mechanisms, clinical pharmacy management, and real-world data on oseltamivir for influenza.
Expert opinion: Oseltamivir is an oral prodrug of oseltamivir carboxylate, an influenza A and B neuraminidase inhibitor. Recently, the therapeutic efficacy of oseltamivir has been demonstrated in several trials. Oseltamivir is generally well-tolerated but may lead to neuropsychiatric events and bleeding. Oseltamivir-resistant influenza virus has been associated with the H275Y mutation in the influenza A(H1N1)pdm09 virus, while most strains are still sensitive to oseltamivir. Dose adjustment for oseltamivir should be based on creatinine clearance and body weight in pediatric patients with renal failure. According to real-world data from Nanfang Hospital, the annual number of patients prescribed oseltamivir declined from 35,711 in 2019 to 8,971 in 2020, with marked increases in 2022 (20,213) and 2023 (18,071). Among the 206 inpatients, children aged <6 years who were treated with oseltamivir had the shortest duration to defervescence.
Keywords: Clinical pharmacy management; Oseltamivir; influenza; prevention; tolerability; treatment.